• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke after thoracic endovascular aortic aneurysm repair. A silent enemy that needs more caution
Curr Pharm Des. 2022 Feb 25. doi: 10.2174/1381612828666220225121742. Online ahead of print.NO ABSTRACTPMID:35232340 | DOI:10.2174/1381612828666220225121742
Source: Current Pharmaceutical Design - March 2, 2022 Category: Drugs & Pharmacology Authors: Georgios Karaolanis Demetrios Moris Efstratios Georgakarakos Konstantinos Donas Source Type: research

Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment
Atherosclerosis, the chronic accumulation of cholesterol-rich plaque within arteries, is associated with a broad spectrum of cardiovascular diseases including myocardial infarction, aortic aneurysm, peripheral vascular disease, and stroke. Atherosclerotic cardiovascular disease remains a leading cause of mortality in high-income countries and recent years have witnessed a notable increase in prevalence within low- and middle-income regions of the world. Considering this prominent and evolving global burden, there is a need to identify the cellular mechanisms that underlie the pathogenesis of atherosclerosis to discover nov...
Source: Frontiers in Pharmacology - December 22, 2021 Category: Drugs & Pharmacology Source Type: research

Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems.
HOMOCYSTEINE AND HOMOCYSTEINE-RELATED COMPOUNDS: AN OVERVIEW OF THE ROLES IN THE PATHOLOGY OF THE CARDIOVASCULAR AND NERVOUS SYSTEMS. Can J Physiol Pharmacol. 2018 Aug 21;: Authors: Djuric D, Jakovljevic V, Zivkovic VI, Srejovic IM Abstract Homocysteine, sulfhydryl group containing amino acid, is intermediate product during metabolism of the amino acids methionine and cysteine. Hyperhomocysteinema (HHcy) is used as a predictive risk factor for cardiovascular disorders, the stroke progression, screening for inborn errors of Met metabolism, and as a supplementary test for vitamin B12 deficiency. Two org...
Source: Canadian Journal of Physiology and Pharmacology - August 21, 2018 Category: Drugs & Pharmacology Authors: Djuric D, Jakovljevic V, Zivkovic VI, Srejovic IM Tags: Can J Physiol Pharmacol Source Type: research

Leptin, cardiovascular diseases and type 2 diabetes mellitus.
Abstract Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - June 7, 2018 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Banach M Tags: Acta Pharmacol Sin Source Type: research

Homocysteine and non-cardiac vascular disease.
Abstract Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are ...
Source: Current Pharmaceutical Design - March 17, 2017 Category: Drugs & Pharmacology Authors: Katsiki N, Perez-Martinez P, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists
Abstract Apparent treatment-resistant hypertension (aTRH) is defined as blood pressure (BP) >140/90 mmHg despite three different antihypertensive drugs including a diuretic. aTRH is associated with an increased risk of cardiovascular events, including stroke, chronic renal failure, myocardial infarction, congestive heart failure, aortic aneurysm, atrial fibrillation, and sudden death. Preliminary studies of renal nerve ablation as a therapy to control aTRH were encouraging. However, these results were not confirmed by the Symplicity 3 trial. Therefore, attention has refocused on drug therapy. Secondary forms o...
Source: Drugs - March 19, 2015 Category: Drugs & Pharmacology Source Type: research